Action L7R LIPIDOR AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Lipidor AB Deutsche Boerse AG

Actions

L7R

SE0012558617

Temps Différé Deutsche Boerse AG
Autres places de cotation
 09:46:25 17/07/2024 		Varia. 5j. Varia. 1 janv.
0,0042 EUR 0,00 % Graphique intraday de Lipidor AB +2 000,00 % -87,20 %
22/05 Lipidor AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
22/04 Lipidor AB (publ) reporte la publication du rapport annuel 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue
Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants
Lipidor announces final outcome in the rights issue
Lipidor announces preliminary outcome in the rights issue
Last day of trading in unit rights in Lipidor's rights issue
Bulletin from the Annual General Meeting of Lipidor AB (publ)
Lipidor invites to digital presentations with Q&A
Today the subscription period in Lipidor's rights issue begins
Lipidor publishes prospectus due to upcoming rights issue of units
Lipidor AB (publ) publishes interim report for Q1 2024
Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)
Lipidor AB (publ) publishes annual report for 2023
NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)
Lipidor AB announces new date for publication of Annual Report 2023
Lipidor AB Postpones the Publication of Annual Report for 2023
NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)
Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study
Lipidor completes planned divestment of shares in Emollivet
Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LIPI
  4. Action L7R
  5. Actualités Lipidor AB
  6. Autres langues